REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Shaperon Co.,Ltd. (South Korea)

Main Activities: Biological Product (except Diagnostic) Manufacturing
Full name: Shaperon Co.,Ltd. Profile Updated: July 04, 2023
Buy our report for this company USD 19.99 Most recent financial data: 2022 Available in: English Download a sample report

Shaperon Co.,Ltd. is engaged in the biopharmaceutical business. The company also offers products such as pneumonia therapy, alzheimer's disease therapy and atopic therapy as well as other medicines. Shaperon Co.,Ltd. was incorporated in 2008 and is based in Seoul, South Korea.

Headquarters
606-ho, 174-10, Jagok-ro Gangnam-gu Seoul
Seoul; Seoul;

Contact Details: Purchase the Shaperon Co.,Ltd. report to view the information.

Basic Information
Total Employees:
Purchase the Shaperon Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Shaperon Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Shaperon Co.,Ltd. report to view the information.
Incorporation Date:
October 01, 2008
Key Executives
Purchase this report to view the information.
CEO
Purchase this report to view the information.
Non-Executive Independent Director
Purchase this report to view the information.
Non-Executive Independent Director
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Senior Managing Director
Company Performance
Financial values in the chart are available after Shaperon Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
282.53%▲
Total operating revenue
282.53%▲
Operating profit (EBIT)
-5.39%▼
EBITDA
-4.86%▼
Net Profit (Loss) for the Period
55.22%▲
Total assets
30.07%▲
Total equity
20%▲
Operating Profit Margin (ROS)
1450.31%▲
Net Profit Margin
4024.78%▲
Return on Equity (ROE)
61.23%▲
Debt to Equity Ratio
0.12%▲
Quick Ratio
-12.04%▼
Cash Ratio
-3.07%▼

Similar companies

Samsung Biologics Co., Ltd.
 
Janssen Vaccines Corp.
Bioplus Co., Ltd.
 
GenoFocus, Inc.
U2Bio Co. Ltd.
 
Bio Solution Co.,Ltd.
Cellid Co.,Ltd.
 
Eutilex Co.,Ltd.
NeoImmuneTech. Inc.
 
Inno Therapy Inc.

To view more information, Request a demonstration of the EMIS service

USD 19.99
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo